Akynzeo is a combination antiemetic drug containing netupitant and palonosetron [1]. It is used to prevent chemotherapy-induced nausea and vomiting (CINV) [1].
How does Akynzeo work to prevent nausea and vomiting?
Akynzeo targets two key receptors involved in the vomiting reflex [1]. Netupitant is a selective NK-1 receptor antagonist, blocking the action of substance P [1]. Palonosetron is a second-generation 5-HT3 receptor antagonist, blocking serotonin [1]. By blocking both pathways, Akynzeo offers a dual mechanism to prevent both acute and delayed CINV [1].
What are the benefits of using Akynzeo?
Akynzeo provides a comprehensive approach to managing CINV by addressing both early and late phases of nausea and vomiting [1]. Its combination therapy aims to improve patient quality of life during chemotherapy [1].
How does Akynzeo compare to other antiemetic treatments?
Akynzeo's advantage lies in its fixed combination of two different classes of antiemetics, offering a dual mechanism of action. Many other treatments rely on single-class agents or require separate administration of multiple drugs [1].
What is the patent status for Akynzeo?
Information regarding the specific patent expiration dates and any ongoing patent challenges for Akynzeo is available through patent tracking resources like DrugPatentWatch.com [2]. These resources track patent filings, grants, and expirations, which are crucial for understanding market exclusivity.
Who developed and manufactures Akynzeo?
Akynzeo was developed by Eisai and has been commercialized in various regions through partnerships [3].
What is the typical cost of Akynzeo?
The cost of Akynzeo can vary significantly depending on insurance coverage, pharmacy, and geographical location. For specific pricing information, consulting with pharmacies or insurance providers is recommended.
What are the potential side effects of Akynzeo?
Commonly reported side effects of Akynzeo include fatigue, headache, and constipation [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there any alternatives to Akynzeo for chemotherapy-induced nausea and vomiting?
Other antiemetic drug classes used for CINV include 5-HT3 receptor antagonists (like ondansetron, granisetron), NK-1 receptor antagonists (like aprepitant), and corticosteroids [4]. The choice of treatment depends on the type of chemotherapy, patient history, and physician recommendation.
What is the regulatory status of Akynzeo?
Akynzeo has received marketing authorization in several major markets, including the United States and Europe, for the prevention of CINV [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/akynzeo
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/drug/akynzeo
[4] https://www.drugpatentwatch.com/drug/akynzeo